Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.41 is 261% above its 1-year average of 0.11, near the high end of its 1-year range (0.00–0.41).
As of the fiscal period ended Tuesday, June 30, 2026. 260.70% above its 12-month average of 0.11.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.41.
DEBT TO EQUITY RATIO
0.41
DEBT TO EQUITY RATIO AVG TTM
0.11
DEBT TO EQUITY RATIO AVG 3Y
0.00
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+260.70%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
+272.21%
vs the sector median at left
Actuate Therapeutics Inc
Market Cap
$19.42M
Debt to Equity Ratio
0.41
TTM Avg
0.11
3Y Avg
0.00
5Y Avg
N/A
Market Cap
$19.77M
Debt to Equity Ratio
0.12
TTM Avg
0.17
3Y Avg
0.10
5Y Avg
0.07
Market Cap
$18.65M
Debt to Equity Ratio
0.00
TTM Avg
0.01
3Y Avg
0.02
5Y Avg
0.02
Market Cap
$18.41M
Debt to Equity Ratio
1.80
TTM Avg
1.53
3Y Avg
5.45
5Y Avg
5.45
Market Cap
$18.30M
Debt to Equity Ratio
N/A
TTM Avg
0.00
3Y Avg
0.02
5Y Avg
0.01
Market Cap
$17.39M
Debt to Equity Ratio
0.77
TTM Avg
0.78
3Y Avg
0.55
5Y Avg
1.68
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Actuate Therapeutics Inc (ACTU) | $19.42M | 0.41 | 0.11 | 0.00 | N/A |
| Quantum BioPharma Ltd. (QNTM)vs › | $19.77M | 0.12 | 0.17 | 0.10 | 0.07 |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.65M | 0.00 | 0.01 | 0.02 | 0.02 |
| P3 Health Partners Inc. (PIII)vs › | $18.41M | 1.80 | 1.53 | 5.45 | 5.45 |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.30M | N/A | 0.00 | 0.02 | 0.01 |
| NextCure, Inc. (NXTC)vs › | $20.53M | 0.35 | 0.12 | 0.08 | 0.06 |
| Cosmos Health Inc. (COSM)vs › | $17.39M | 0.77 | 0.78 | 0.55 | 1.68 |
| Lipocine Inc. (LPCN)vs › | $17.31M | 0.00 | 0.01 | 0.01 | 0.07 |
| PAVmed Inc. (PAVM)vs › | $17.07M | 0.49 | 0.39 | 0.39 | 2.76 |
| Marker Therapeutics, Inc. (MRKR)vs › | $16.84M | 0.00 | 0.00 | 0.10 | 0.18 |
Debt/Equity
0.41
Current Ratio
1.25
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.41 |
| 2026-03-31 | 0.11 |
| 2025-12-31 | 0.05 |
| 2025-09-30 | 0.00 |
| 2025-06-30 | 0.00 |
| 2025-03-31 | 0.00 |
| 2024-12-31 | 0.00 |
| 2024-09-30 | 0.00 |
| 2024-06-30 | -0.06 |
| 2024-03-31 | -0.05 |
| 2023-12-31 | 0.00 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
